Science Corporation, a brain-computer interface (BCI) developer founded by Neuralink co-founder Max Hodak, has acquired the intellectual property (IP) and related assets for the Pixium Vision Prima implant. This acquisition includes the retinal implant technology developed by Pixium Vision. The Prima System, which is a photovoltaic substitute of photoreceptors, has already received FDA breakthrough device designation. It is designed for patients with atrophic dry age-related macular degeneration (AMD) and allows for simultaneous use of central prosthetic and peripheral natural vision.
Pixium Vision, based in France, had been looking for a potential buyer and Science Corporation saw an opportunity to further develop BCI technology for vision restoration through the acquisition of the Prima System. Science Eye, another product developed by Science Corporation, is a visual prosthesis targeting retinitis pigmentosa (RP) and dry AMD. The company believes that the Prima implant will expand their IP portfolio and provide continuity and a future for patients enrolled in Pixium clinical trials.
CEO Max Hodak expressed excitement about the acquisition, stating that Science Corporation is now developing innovative products using two different modalities. With the addition of the Prima implant technology, Science Corporation aims to continue their mission of helping patients with vision impairments. Outgoing Pixium CEO Lloyd Diamond expressed confidence in the acquisition, believing that Prima now has a home with a team dedicated to helping patients. The terms of the deal were not disclosed, but both companies are committed to working together to advance BCI technology for the benefit of patients.
Science Corporation’s development of innovative products using two different modalities will enable them to help even more patients with vision impairments in new ways. By acquiring Pixium’s IP and related assets for the Prima implant technology, they can continue their mission of creating cutting-edge solutions that restore or enhance visual function in people who have lost it due to various conditions such as AMD or RP.
The addition of this new technology to their existing portfolio expands Science Corporation’s offerings beyond just visual prostheses to include retinal implants that can be used simultaneously with central prosthetic and peripheral natural vision. This enables them to provide even more comprehensive solutions for patients who suffer from various types of vision loss.
With their commitment to working together towards advancing BCI technology, both companies are excited about what this new partnership will bring in terms of improving patient outcomes and providing hope for those who have lost their sight.
Overall, this acquisition marks an important step forward in BCI technology development for vision restoration and highlights how collaboration between companies can lead to groundbreaking advancements that benefit millions of people worldwide.
